以岭药业：全资孙公司阿那曲唑原料药获上市申请批准通知书

Core Viewpoint - Yiling Pharmaceutical (002603.SZ) announced that its wholly-owned subsidiary, Wanyang Hengshui Pharmaceutical Co., Ltd., has received the approval notice for the listing application of Anastrozole chemical raw material from the National Medical Products Administration [1] Group 1: Product Approval - The listing application for Anastrozole, a drug widely used for treating estrogen-related tumors, particularly in postmenopausal hormone receptor-positive (HR+) female breast cancer patients, has been approved [1] - Yiling Pharmaceutical's wholly-owned subsidiary, Beijing Yiling Biotechnology Co., Ltd., holds the formulation approval for Anastrozole tablets, which are part of a centralized procurement product [1] Group 2: Production Integration - The company expects to achieve integrated production of raw materials and formulations for Anastrozole this year [1]